Net Cash Provided by (Used in) Financing Activities of Cytosorbents Corp from 31 Dec 2010 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Cytosorbents Corp quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2010 to 31 Mar 2025.
  • Cytosorbents Corp Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $6,832,134.
  • Cytosorbents Corp annual Net Cash Provided by (Used in) Financing Activities for 2024 was $9,330,704, a 36% decline from 2023.
  • Cytosorbents Corp annual Net Cash Provided by (Used in) Financing Activities for 2023 was $14,474,210, a 192% increase from 2022.
  • Cytosorbents Corp annual Net Cash Provided by (Used in) Financing Activities for 2022 was $4,959,642, a 593% increase from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Cytosorbents Corp Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $6,832,134 +$7,403,896 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2024 $571,762 -$1,256,045 -184% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q1 2023 $684,283 +$724,642 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $40,359 -$116,912 -153% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q1 2021 $76,553 -$17,805,103 -100% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q1 2020 $17,881,656 +$15,877,095 +792% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q1 2019 $2,004,561 -$4,438,389 -69% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q1 2018 $6,442,950 +$6,266,621 +3554% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q1 2017 $176,329 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q1 2015 $10,011,841 +$208,626 +2.1% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2015 2015 Q1
Q1 2014 $9,803,215 +$9,353,215 +2078% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q1 2013 $450,000 -$1,250,001 -74% 01 Jan 2013 31 Mar 2013 10-Q 14 May 2014 2014 Q1
Q1 2012 $1,700,001 -$268,749 -14% 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013 2013 Q1
Q1 2011 $1,968,750 01 Jan 2011 31 Mar 2011 10-Q 15 May 2012 2012 Q1

Cytosorbents Corp Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $9,330,704 -$5,143,506 -36% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $14,474,210 +$9,514,568 +192% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $4,959,642 +$4,244,443 +593% 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024 2023 FY
2021 $715,199 -$65,633,131 -99% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2024 2023 FY
2020 $66,348,330 +$58,170,651 +711% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2023 2022 FY
2019 $8,177,679 -$9,288,174 -53% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
2018 $17,465,853 -$2,657,220 -13% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021 2020 FY
2017 $20,123,073 +$15,058,866 +297% 01 Jan 2017 31 Dec 2017 10-K 05 Mar 2020 2019 FY
2016 $5,064,207 -$6,576,035 -56% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
2015 $11,640,242 +$1,623,336 +16% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
2014 $10,016,906 +$5,814,219 +138% 01 Jan 2014 31 Dec 2014 10-K 31 Mar 2015 2014 FY
2013 $4,202,687 -$7,919 -0.19% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2015 2014 FY
2012 $4,210,606 +$198,605 +5% 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014 2013 FY
2011 $4,012,001 +$1,909,253 +91% 01 Jan 2011 31 Dec 2011 10-K 03 Apr 2013 2012 FY
2010 $2,102,748 01 Jan 2010 31 Dec 2010 10-K 30 Mar 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.